46 Woodstock Road,
Oxford, OX2 6HT
Principal, Life Sciences
Sally focuses on the creation of new biotech businesses, bringing deep oncology research expertise and experience translating cutting-edge science into company formation. She joined Oxford Science Enterprises in February 2021.
Sally was previously an Anderson Cancer Center Post-Doctoral Fellow at the Rockefeller University in New York where her research focused on genetic instability at the very earliest stages of cancer development. Prior to this, she completed a PhD at the Francis Crick Institute in London where she uncovered an important role for polypoid cells in driving cancer evolution.
Sally has contributed to research that’s been published in leading journals such as Nature Genetics, Nature Communications and Cancer Discovery.
Sally has also studied corporate finance at NYU and consulted for The Solution Lab.

Oxford researchers & innovators
We partner with researchers and innovators across Oxford, Harwell and Culham to explore commercial potential, co-create ventures and build companies.

Investors
We’ve raised over £850m from global investors keen to access Oxford’s diverse, world-leading science. Our shareholders don’t just back OSE – many also co-invest alongside us.

Co-investors
We partner with specialist global investors to fund and scale our companies – from pre-seed to growth. Together, OSE and our co-investors have invested more than £3bn.